Floatz logo

Mesna

Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)

Masonic Cancer Center, University of MinnesotaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET) cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Barbara Ann Karmanos Cancer Institute
Phase 3BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2B
Irinotecan
National Cancer Institute (NCI)
Phase 1CCC
Vorinostat
National Cancer Institute (NCI)
Phase 1CCC
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 1CCC

View all 30 →

Same molecule, other indications

Mesna is also rated in:

Hodgkin's LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
69 / 100
View asset →
NK/T-cell LymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →